Floatz logo

yl201

Metastatic Castration-resistant Prostate Cancer (mCRPC)

MediLink Therapeutics (Suzhou) Co., Ltd.Phase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

19 Active assets in the Metastatic Castration-resistant Prostate Cancer (mCRPC) cohort.

Asset / SponsorPhaseRating
FLUDROCORTISONE
Merck Sharp & Dohme LLC
Phase 3B
Opevesostat
Merck Sharp & Dohme LLC
Phase 3B
Capivasertib
Karolinska Institutet
Phase 3CCC
Abiraterone Acetate
Jiangsu HengRui Medicine Co., Ltd.
Phase 2CCC
PREDNISONE TABLETS
Merck Sharp & Dohme LLC
Phase 3CCC

View all 22 →

Same molecule, other indications

yl201 is also rated in:

small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
cancerDormant
CC
Indicative ·
45 / 100
View asset →
Advanced Solid TumorDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →